- Allogene reports patient death tied to its CAR-T drug
Allogene Therapeutics said that one of its patients in a clinical trial for its multiple myeloma CAR-T drug died of fungal pneumonia. - Patient death tied to CRISPR Therapeutics’ CAR-T therapy
An off-the-shelf CAR-T cell therapy being developed by CRISPR Therapeutics saw positive results in some patients with advanced B-cell lymphoma, but was also tied to a patient’s death. - FDA halts California drugmaker’s CAR-T trial after patient death
The FDA halted San Diego-based drugmaker Poseida Therapeutics’ clinical trial of a CAR-T therapy after a patient died. - FDA puts clinical hold on Cellectis CAR-T trial after patient dies of cardiac arrest
The FDA put a clinical hold on French drugmaker Cellectis’ trial for its off-the-shelf CAR-T therapy after a patient died of cardiac arrest.
More articles on pharmacy:
Biden team to meet with COVID-19 vaccine-makers this week
HHS partners with 19 pharmacy networks for COVID-19 vaccine allocation
‘Puzzle without the edge and corner pieces’: 2 experts weigh in on Pfizer, Moderna vaccine trial news
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
